UCB Weighs Up Alzheimer’s Drug Future After Phase II Miss And Roche Exit
The Phase II results suggest subgroups of patients could possibly benefit from bepranemab, but with Roche’s exit, the odds are stacked against the anti-tau candidate.
The Phase II results suggest subgroups of patients could possibly benefit from bepranemab, but with Roche’s exit, the odds are stacked against the anti-tau candidate.